FDA's Dermatologic Drugs Advisory Committee
This article was originally published in The Tan Sheet
Executive Summary
Discussion topics for the panel's Sept. 22-23 meeting include the fungal nail infection onychomycosis and the "determination of endpoints for clinical trials investigating treatment of onychomycosis," an Aug. 16 Federal Register notice states. The meeting will be held in Conference Rooms D&E of FDA's Parklawn Building beginning at 8:30 a.m. on both days
You may also be interested in...
Supplement GMP Warning Letters Make Modest Debut In 2010
Finalization of a settlement between the Federal Trade Commission and Rexall Sundown regarding unsupported cellulite treatment claims for the firm's Cellasene dietary supplement hinges upon approval of two related class action settlements pending in California and Florida, according to FTC
In Brief
Combe sells most of its OTC brands
People In Brief
Perrigo promotes in pricing, planning